-
Leukemia & Lymphoma Apr 2006Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma. It is most commonly used in the treatment of Hodgkin's disease. The use of...
Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma. It is most commonly used in the treatment of Hodgkin's disease. The use of procarbazine-containing chemotherapeutic regimens in non-Hodgkin's lymphoma fell out of favor with the advent of CHOP. We report two patients with relapsed and/or refractory follicular lymphoma that achieved a complete and durable remission with a prolonged course of daily procarbazine.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Monoamine Oxidase Inhibitors; Procarbazine; Remission Induction; Stem Cell Transplantation
PubMed: 16690522
DOI: 10.1080/10428190600591517 -
Report on Carcinogens : Carcinogen... 2004
Topics: Animals; Antineoplastic Agents; Carcinogenicity Tests; Carcinogens; Female; Government Regulation; Guidelines as Topic; Haplorhini; Humans; Male; Mice; Models, Biological; Occupational Exposure; Procarbazine; Rats; United States
PubMed: 21089949
DOI: No ID Found -
IARC Monographs on the Evaluation of... May 1981
Topics: Animals; Carcinogens; Chemical Phenomena; Chemistry; Female; Haplorhini; Humans; Male; Maternal-Fetal Exchange; Mice; Neoplasms, Experimental; Pregnancy; Procarbazine; Rats; Reproduction; Teratogens
PubMed: 6792050
DOI: No ID Found -
Report on Carcinogens : Carcinogen... 2002
Topics: Animals; Carcinogens; Environmental Exposure; Government Regulation; Humans; Procarbazine; United States
PubMed: 15334716
DOI: No ID Found -
AJR. American Journal of Roentgenology Sep 1978
Topics: Humans; Lung Diseases; Male; Middle Aged; Pleural Effusion; Procarbazine; Radiography
PubMed: 99008
DOI: 10.2214/ajr.131.3.527 -
Toxicology and Applied Pharmacology Sep 1985Procarbazine was shown to decrease spermatogenesis in male mice in a dose-dependent manner. Significant decreases (44% of controls) in spermatogenesis were observed when...
Procarbazine was shown to decrease spermatogenesis in male mice in a dose-dependent manner. Significant decreases (44% of controls) in spermatogenesis were observed when a dose of 400 mg/kg was administered 18 days prior to determination of sperm count. Procarbazine caused no significant acute spermatocidal activity in vivo. Procarbazine-associated decreases in spermatogenesis were thus used as an index of toxicity to developing spermatid cells. Procarbazine analogs were synthesized that had deuterium substituted for hydrogen at the benzylic position, N-isopropyl-alpha-(2-methylhydrazino)-p-[alpha, alpha-2H2]toluamide (d2-procarbazine), or at the methyl position, N-isopropyl-alpha-(2-[alpha, alpha, alpha-2H3]methylhydrazino)-p-toluamide (d3-procarbazine). Spermatogenesis decreases caused by d3-procarbazine were essentially the same as with procarbazine in mice (66% of controls at a dose of 200 mg/kg), but d2-procarbazine was nontoxic to developing sperm cells (99% of control at a dose of 200 mg/kg). The decrease in toxicity caused by deuterium substitution at the benzylic position, coupled with the absence of an effect with the methyl-labeled analog, indicate the requirement for regioselective oxidative metabolism of procarbazine at the benzylic position prior to the toxic event.
Topics: Animals; Deuterium; Injections, Intraperitoneal; Isotopes; Male; Mice; Procarbazine; Sperm Count; Spermatogenesis; Structure-Activity Relationship
PubMed: 4024121
DOI: 10.1016/0041-008x(85)90089-4 -
Report on Carcinogens : Carcinogen... 2011
Topics: Animals; Antineoplastic Agents; Female; Humans; Hydrochloric Acid; Male; Mice; Neoplasms; Procarbazine; Rats
PubMed: 21863086
DOI: No ID Found -
Medical and Pediatric Oncology 1988A case of a previously unrecognized form of hypersensitivity to procarbazine characterized by a nonpigmented fixed drug eruption is reported. Despite skin testing,...
A case of a previously unrecognized form of hypersensitivity to procarbazine characterized by a nonpigmented fixed drug eruption is reported. Despite skin testing, association of the skin lesion to procarbazine could be determined only by drug rechallenge. Various aspects of procarbazine hypersensitivity reactions as well as the pathogenesis and importance of the fixed drug eruption are discussed.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Eruptions; Hodgkin Disease; Humans; Male; Mechlorethamine; Prednisone; Procarbazine; Skin Tests; Vinblastine; Vincristine
PubMed: 2462159
DOI: 10.1002/mpo.2950160605 -
Cancer Chemotherapy and Pharmacology 1983An in vivo assay of the activity of procarbazine, N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride, and several metabolic intermediates against...
The in vivo cytotoxic activity of procarbazine and procarbazine metabolites against L1210 ascites leukemia cells in CDF1 mice and the effects of pretreatment with procarbazine, phenobarbital, diphenylhydantoin, and methylprednisolone upon in vivo procarbazine activity.
An in vivo assay of the activity of procarbazine, N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride, and several metabolic intermediates against IP-implanted L1210 leukemia cells in CDF1 male mice is described. Treatment of tumor-bearing mice with procarbazine at doses of 300-500 mg/kg IP increased the mean lifespan of treated mice by 29%-32% relative to that of untreated animals. Procarbazine treatment with doses of 200-400 mg/kg/day given IP for 3 consecutive days increased mean lifespan by 39%-46%. The major circulating metabolite, azoprocarbazine (N-isopropyl-alpha-(2-methylazo)-p-toluamide), was as active as procarbazine when administered at equivalent doses for 3 consecutive days. A 2:1 mixture of azoxyprocarbazines (N-isopropyl-alpha-(2-methyl-ONN-azoxy)-: and N-isopropyl-alpha-(2-methyl-NNO-azoxy)-p-toluamide) was more active than procarbazine, increasing mean lifespan by 76% using the 3-consecutive-day dose schedule. The effects of pretreatment with procarbazine and drugs that are often co-administered with procarbazine, i.e., phenobarbital, diphenylhydantoin, and methylprednisolone, upon procarbazine anticancer activity against L1210 ascites leukemia cells was also determined. Pretreatment of CDF1 male mice with phenobarbital and diphenylhydantoin for 7 days was found to increase the antineoplastic activity of procarbazine by 13%-24%. Pretreatment with methylprednisolone did not significantly alter procarbazine activity. The effects of pretreatment with procarbazine, which is often administered daily for a period of 2-4 weeks, on procarbazine antineoplastic activity were varied. The results of these preliminary pretreatment studies combined with the finding that procarbazine metabolites have antitumor activity that is equal to or greater than that of the parent drug suggest that current clinical protocols that use procarbazine along with agents capable of altering procarbazine metabolism may involve drug interactions that alter the efficacy of procarbazine as an anticancer agent.
Topics: Animals; Drug Interactions; Leukemia L1210; Male; Methylprednisolone; Mice; Mice, Inbred Strains; Phenobarbital; Phenytoin; Procarbazine
PubMed: 6627598
DOI: 10.1007/BF00254261 -
Scandinavian Journal of Haematology Feb 1980A total of 44 patients with Hodgkin's disease and 23 patients with non-Hodgkin malignant lymphoma were treated with MOPP-combination chemotherapy. 4 patients with...
A total of 44 patients with Hodgkin's disease and 23 patients with non-Hodgkin malignant lymphoma were treated with MOPP-combination chemotherapy. 4 patients with Hodgkin's disease and 8 with non-Hodgkin lymphoma developed urticaria or maculo-papular rash. This frequency of hypersensitivity reactions is higher than that expected from the few cases reported in the literature.
Topics: Drug Hypersensitivity; Hodgkin Disease; Humans; Lymphoma; Procarbazine; Urticaria
PubMed: 7375814
DOI: 10.1111/j.1600-0609.1980.tb02359.x